Surmodics (SRDX)
(Delayed Data from NSDQ)
$41.80 USD
+0.02 (0.05%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.80 USD
+0.02 (0.05%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
Zacks News
DexCom Introduces Registry to Monitor Outcomes of G6 System
by Zacks Equity Research
DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock, thanks to solid prospects.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
Why Is SurModics (SRDX) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health's BioReference Laboratories Introduces NGS Assay
by Zacks Equity Research
OPKO Health's (OPK) OnkoSight Advanced is a NGS assay that facilitates revolutionary DNA mutational profiling of tumor samples.
Baxter (BAX) Attains FDA De Novo Authorization for Theranova
by Zacks Equity Research
Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.
Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval
by Zacks Equity Research
Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care
Here's Why You Should Retain Inogen in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects
Smith+Nephew Unveils Digital Platform to Boost Patient Care
by Zacks Equity Research
With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.
Here's Why You Should Retain HMS Holdings in Your Portfolio
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) , thanks to solid prospects.
Thermo Fisher Unveils Suite of Hematology-Oncology Solutions
by Zacks Equity Research
The Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from Thermo Fisher's (TMO) new portfolio of hematology-oncology solutions.
Masimo Releases Favorable Study Results on Pulse Oximetry
by Zacks Equity Research
The pulse oximetry study result should be a major breakthrough for Masimo (MASI) to capture the neonatal patient care market.
Why Hold Strategy is Apt for Varian Medical (VAR) Stock Now
by Zacks Equity Research
Investor confidence is high in Varian Medical (VAR) stock at the moment.
Here's Why You Should Add NextGen Stock to Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
PerkinElmer's Hand Sanitizer Analyzer to Test for Methanol
by Zacks Equity Research
PerkinElmer's (PKI) Hand Sanitizer Analyzer can help lab professionals and scientists all over the world in their fight against COVID-19.
PerkinElmer Launches Workstations for Coronavirus Testing
by Zacks Equity Research
PerkinElmer's (PKI) scalable and modular explorer automated workstations simplify testing workflows, thereby expediting the process of SARS-CoV-2 RT-PCR testing.
Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness
by Zacks Equity Research
The FDA approval of Masimo's (MASI) PVi system will enable patient safety.
Surmodics (SRDX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.
SurModics (SRDX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 110.00% and 8.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add AMN Healthcare to Your Portfolio
by Zacks Equity Research
Investor confidence is high in AMN Healthcare (AMN) stock, thanks to solid prospects.